Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.37 (
CNPase
)
539
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The levels of GPC phosphocholine phosphodiesterase, pNP phosphocholine phosphodiesterase,
CNPase
, and
UDP
galactose: ceramide galactosyltransferase activities were estimated with pure cultures of oligodendrocytes and astrocytes; mixed primary glial cells cultures; C-6 cells; and CNS tissue of the dysmyelinating md rat, the jimpy mouse, and the quaking mouse. The highest activity of GPC and pNP phosphocholine phosphodiesterases as with
CNPase
and C gal T was found in the pure cultured oligodendrocytes. C-6 cells had very low or undetectable activities for these two phosphodiesterases but possessed very high
CNPase
activity. The activity of GPC phosphocholine phosphodiesterase was significantly decreased in the CNS tissue of the md rat and the jimpy and the quaking mouse. Similar reductions were observed for the pNP phosphocholine phosphodiesterase,
CNPase
, and C gal T activities. The selective cellular enrichment in oligodendrocytes of the GPC phosphocholine phosphodiesterase activity and decreases of its activity in three dysmyelinating mutants in the same ratio as for
CNPase
and C gal T suggest that GPC phosphocholine phosphodiesterase is a myelin marker enzyme and it may reflect the quantity of myelin and oligodendrocyte present.
...
PMID:Glycerophosphorylcholine phosphocholine phosphodiesterase activity in cultured oligodendrocytes, astrocytes, and central nervous tissue of dysmyelinating rodent mutants. 131 6
Methylmercury (MeHg) and triethyllead (Et3Pb) are known to cause neurologic impairment in human and in several animal models. In the developing central nervous system the formation of myelin is particularly vulnerable. To obtain more information on the toxic mechanisms related to dysmyelination, the effects of MeHg and Et3Pb on two marker enzymes of myelination was assessed in developing rats. From the 5th day of life intraperitoneal injections of MeHgCl or Et3PbCl at doses of 0.05 to 5 mg/kg body weight were administered to the rats three times a week. They were decapitated at the 21 to 23rd (group A) or at the 28 to 31st postnatal day (group B). The animals treated with 2 mg/kg MeHg or Et3Pb appeared normal and the rate of growth was unchanged compared with that of control rats. A decreased activity of the enzymes
UDP
galactose:ceramide galactosyltransferase (CGalT) and
2',3'-cyclic-nucleotide 3'-phosphodiesterase
(CNP) was apparent already at doses of 0.1 mg/kg in group B rats. (MeHg, 18 and 16%, respectively; Et3Pb, 11 and 14%) and the values decreased further with increased toxic doses. In the MeHg-treated animals the exposure time was decisive for the effect; thus in group A of MeHg-treated animals the change in enzyme activities was minimal at doses which in group B had an inhibitor effect. The activities of brain acetylcholinesterase and succinate dehydrogenase were not affected. The results emphasize a common early effect of MeHg and Et3Pb on enzymes associated with myelination in the developing central nervous system.
...
PMID:UDPgalactose:ceramide galactosyltransferase and 2',3'-cyclic-nucleotide 3'-phosphodiesterase activities in rat brain after long-term exposure to methylmercury or triethyllead. 298 18